US9315514, Buprenorphine BUPRENORPHINE BDBM50354578 US11534436, Compound buprenorphine US10752592, Compound buprenorphine
BDBM50026603 Buprenorphine CHEBI:3216
BDBM179909 US9133125, Table D, buprenorphine
Buprenorphine-3--Beta--D-glucuronide BDBM83448 SMR001338851 cid_44246524 MLS002320705
2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(15S)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol(Buprenorphine) Buprenorphine2-(3-cyclopropylmethyl-11-hydroxy-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl)-3,3-dimethyl-2-butanol( CHEMBL560511 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol BUPRENORPHINE Buprenorphine(-) Buprenorphine(+) BDBM50028147
- Goehring, R; Tafesse, L; Yao, J Buprenorphine analogs US Patent US8969358 (2015)
- Kyle, DJ Quarternized buprenorphine analogs US Patent US9096606 (2015)
- Cami-Kobeci, G; Polgar, WE; Khroyan, TV; Toll, L; Husbands, SM Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. J Med Chem 54: 6531-7 (2011)
- Husbands, SM; Lewis, JW Structural determinants of efficacy for kappa opioid receptors in the orvinol series: 7,7-spiro analogues of buprenorphine. J Med Chem 43: 139-41 (2000)
- Traynor, JR; Guo, L; Coop, A; Lewis, JW; Woods, JH Ring-constrained orvinols as analogs of buprenorphine: differences in opioid activity related to configuration of C(20) hydroxyl group. J Pharmacol Exp Ther 291: 1093-9 (1999)
- Schoultz, BW; Hj?rnevik, T; Reed, BJ; Marton, J; Coello, CS; Willoch, F; Henriksen, G Synthesis and evaluation of three structurally related¹8F-labeled orvinols of different intrinsic activities: 6-O-[¹8F]fluoroethyl-diprenorphine ([¹8F]FDPN), 6-O-[¹8F]fluoroethyl-buprenorphine ([¹8F]FBPN), and 6-O-[¹8F]fluoroethyl-phenethyl-orvinol ([¹8F]FPEO). J Med Chem 57: 5464-9 (2014)
- Functional Assay (GTPgammaS Binding) The EC50 and Imax for μ opioid receptors was determined using a [35S]GTPγS binding assay. This assay measures the functional properties of a compound by quantifying the level of G-protein activation following agonist binding in studies using stably transfected cells, and is considered to be a measure of the efficacy of a compound. Membranes from CHO (Chinese Hamster Ovary) cells that stably expressed the cloned human Mu opioid receptor were used in the experiments. Specifically, in a final volume of 0.5 mL, 12 different concentrations of each test compound were incubated with 7.5 μg of CHO cell membranes that stably expressed the human μ opioid receptor. The assay buffer consisted of 50 mM Tris-HCl, pH 7.4, 3 mM MgCl2, 0.2 mM EGTA, 3 μM GDP, and 100 mM NaCl. The final concentration of [35S]GTPγS was 0.080 nM. Nonspecific binding was measured by inclusion of 10 μM GTPγS. Binding was initiated by the addition of the membranes. After an incubation of 60 min at 30° C., the samples were filtered through Schleicher & Schuell No. 32 glass fiber filters. The filters were washed three times with cold 50 mM Tris-HCl, pH 7.5, and were counted in 2 mL of Ecoscint scintillation fluid. Data are the mean Emax and EC50 values±S.E.M. For calculation of the Emax values, the basal [35S]GTPγS binding was set at 0%, and the 100% [35S]GTPγS binding level was set at the maximum binding achieved with DAMGO. To determine antagonist activity of a compound at the μ opioid receptors, CHO membranes expressing the μ opioid receptor, were incubated with 12 different concentrations of the compound in the presence of 200 nM of the μ agonist DAMGO. The Emax values are the maximal percentage increase of [35S]GTPγS binding induced by a test compound relative to basal [35S]GTPγS binding in the absence of any drug. Data for antagonists are the mean Imax and IC50 values±S.E.M. The calculated EC50 and Imax values for the compounds tested are set forth in Table B, Table C, Table D, and Table E, herein. It should be noted that the GTPγS binding assay described above is performed under conditions such that the observed Emax value for buprenorphine in this assay is at least 50% compared to baseline.